Expression And Role Of PFN2 In Esophageal Squamous Cell Carcinoma

BackgroundThe incidence of esophageal cancer in China ranks fifth in the world,and the main histomathological type is squamous cell carcinoma,with significant regional differences in its distribution.Due to the fact that most patients with esophageal cancer are in the middle and late stages when they are first diagnosed,and the high metastasis rate and high recurrence rate after treatment,the prognosis is poor.Therefore,it is necessary to explore new therapeutic targets to improve the prognosis of patients with esophageal cancer.Profilin 2(PFN2)is an actin binding protein that regulates the actin response and affects cell movement.PFN2 was found to be associated with proliferation,apoptosis,invasion and metastasis of malignant tumors.Bioinformatics showed that PFN2 was highly expressed in esophageal cancer tissue,suggesting that the increased expression level of PFN2 may be related to the pathological process of esophageal cancer.Therefore,PFN2 may be a target gene for the treatment of esophageal cancer.ObjectiveBy detecting the expression of Pfn2 in esophageal squamous cell carcinoma,and combining with clinicopathological data,the relationship between PFN2 expression and age,sex,degree of tumor differentiation,lymph node metastasis,p TNM stage and survival prognosis was analyzed.To explore the role of PFN2 in the proliferation,migration and invasion of human esophageal carcinoma cells through cell function experiments,and to provide a possible related gene target for the treatment of patients with esophageal squamous cell carcinoma.Methods1.The expression of PFN2 protein in paraffin-embedded tissue samples of esophageal squamous cell carcinoma and corresponding adjacent normal tissue samples were detected by immunohistochemistry.The relationship between the expression of PFN2 protein and the age,sex,degree of tumor differentiation,lymph node metastasis,p TNM stage and survival time of tumor patients was analyzed.2.Esophagus cancer cell lines KYSE410 and EC109 were selected and transfected by encapsulating PFN2 overexpression plasmid with Lipo Genet M2000 Plus Transfection Reagen liposome.3.After transfection,fluorescence detection and real-time quantitative polymerase chain reaction(q RT-PCR)were used to detect transfection efficiency.4.CCK-8 assay was used to detect the proliferation ability of human esophageal cancer cells KYSE410 and EC109.5.The migration ability of these two tumor cell lines under the influence of PFN2 was evaluated by scratch test.6.The invasiveness was studied based on the compartment invasion experiment.Results1.IHC showed that PFN2 expression level was higher in esophageal squamous cell carcinoma tissues than in normal esophageal mucosa tissues(P <0.001).2.The expression of PFN2 was correlated with the degree of tumor differentiation(P<0.05).3.Kaplan-Meier curve and univariate analysis showed that esophageal squamous cell carcinoma patients with high PFN2 expression had a shorter overall survival(P<0.05),and PTNM stage was also an independent prognostic factor of overall survival(P <0.05).4.After transfection with recombinant plasmid pc DNA3.1-pfn2,the expression level of PFN2 m RNA in KYSE410 and EC109 cells was significantly increased(P<0.05).5.CCK-8 assay showed that PFN2 could promote the proliferation of KYSE410 and EC109 cells(all P <0.05).6.Scratch experiment results show that PFN2 can promote KYSE410 and EC109cells’ ability to migrate(P < 0.05).7.Transwell laboratory results showed that Pfn2 promoted the invasion of KYSE410 and EC109 cells(all P <0.01).Conclusions1.The expression of PFN2 was up-regulated in esophageal squamous cells,and its expression was correlated with the degree of tumor differentiation.Patients with high expression of PFN2 had shorter overall survival.These results suggest that PFN2 may be a potential molecular prognostic marker for esophageal squamous cell carcinoma.2.PFN2 can promote the proliferation,migration and invasion of esophageal cancer cells,suggesting that Pf FN2 may be a target for gene therapy in patients with esophageal squamous cell carcinoma.